PRED - Predictive Technology Group, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.6902
-0.0548 (-7.36%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.7450
Open0.7400
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.6600 - 0.7450
52 Week Range0.6600 - 6.9100
Volume421,286
Avg. Volume416,526
Market Cap202.133M
Beta (5Y Monthly)-1.46
PE Ratio (TTM)N/A
EPS (TTM)-0.0780
Earnings DateFeb 13, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Predictive Technology Group Reports Second Quarter Fiscal 2020 Financial Results and Provides Corporate Update

    Predictive Technology Group (OTC PINK: PRED) (“Predictive” or “The Company”), a leader in helping identify barriers that impact women’s health and build healthier families through its innovations to deliver personalized medicine, today announced financial results for the fiscal second quarter ended December 31, 2019 and provided a corporate update. “During the fiscal second quarter and subsequent period, we made significant progress toward our goal of becoming a leading developer of diagnostics and therapeutics targeting the women’s health and fertility markets,” said Bradley C. Robinson, Chief Executive Officer of Predictive Technologies Group.

  • GlobeNewswire

    Predictive Technology Group Announces Beta Test Results for its ARTguide™ Test

    Predictive Technology Group (OTC PINK: PRED) (“Predictive” or “The Company”), a leader in helping identify barriers that impact women’s health and build healthier families through its innovations to deliver personalized medicine, today announced that its wholly owned subsidiary, Predictive Laboratories, received interim beta test results from its ARTguide™ test evaluating over 1,000 patients for risk of endometriosis at beta clinical sites. Initial test results have exceeded the Company’s expectations and parameters established during research and development. Prospective data continue to accumulate regarding pregnancy rates and other treatment outcomes, which will be shared in more detail later this year.

  • GlobeNewswire

    Predictive Technology Group and Atrin Pharmaceuticals Announce Molecular Diagnostic Oncology Development Collaboration

    Predictive Technology Group (OTC PINK: PRED) and Atrin Pharmaceuticals LLC are entering into a collaboration agreement to develop molecular diagnostic tools to facilitate improved selection of cancer patients who would most benefit from treatment with DNA Damage and Response (DDR) inhibitors, including Atrin’s and other small molecule ATR inhibitors. Atrin and Predictive will jointly utilize Predictive Laboratories’ state-of-the-art sequencing capabilities and genomics expertise to identify cancer patients with specific molecular markers that predict the level of clinical response to Atrin’s, and other, targeted therapies.

  • GlobeNewswire

    Predictive Technology Group Reports First Quarter Fiscal 2020 Financial Results and Provides Corporate Update

    Predictive Technology Group, Inc. (OTC Pink: PRED) (“Predictive” or “The Company”), a leader in the development of genetic and molecular diagnostics and companion therapeutics, today announced financial results for the fiscal first quarter ended September 30, 2019 and provided a corporate update. “During our first fiscal quarter, we were able to sustain the momentum that carried us through fiscal 2019,” said Bradley C. Robinson, chief executive officer of Predictive Technology Group. ARTguide™, which helps detect genomic concerns associated with endometriosis and other infertility issues in women, has now been fully commercially launched and we expect material revenues to be generated beginning in calendar 2020.

  • GlobeNewswire

    Predictive Technology Group Provides Stock Trading Platform Update

    Predictive Technology Group, Inc. (OTC Pink: PRED), a leader in the development of genetic and molecular diagnostics and companion therapeutics, today announced that effective on November 6, 2019, the company’s shares commenced trading on the Pink® market from the OTCQX® market previously. Bradley C. Robinson, Chief Executive Officer of Predictive Technology Group, said, “We are aware of the change in trading platform for our shares from the OTCQX® market to the Pink® market. While we are disappointed in and strongly disagree with the OTC’s decision, we remain committed to uplisting to a national securities exchange, and are working through the process of satisfying that exchange’s rigorous listing requirements as expeditiously as possible.

  • GlobeNewswire

    Predictive Technologies Group Engages LifeSci Partners as Communications Partner

    SALT LAKE CITY, Oct. 31, 2019 -- Predictive Technology Group, Inc. (OTCQX: PRED) (“Predictive” or “The Company”), a leader in the development of genetic and molecular.

  • GlobeNewswire

    Predictive Technologies Group PRED Upgrades to OTCQX® Best Market

    Predictive Technology Group, Inc. (PRED), a leader in the development of genetic and molecular diagnostics and companion therapeutics, today announced that the company has been upgraded to the OTCQX® Best Market from the Pink® market. Effective today, the company’s shares will trade under the ticker “PRED.” U.S. investors can find current financial disclosures and Real-Time Level 2 quotes for the company on www.otcmarkets.com. “We are pleased to upgrade to the OTCQX® Best Market and believe this is a testament to the Predictive team who work to continuously improve our financial standards and corporate governance practices,” said Bradley C. Robinson, President and Chief Executive Officer of Predictive Technologies Group.

  • OTC Markets Group Welcomes Predictive Technology Group, Inc. to OTCQX
    PR Newswire

    OTC Markets Group Welcomes Predictive Technology Group, Inc. to OTCQX

    NEW YORK , Oct. 24, 2019 /PRNewswire/ -- OTC Markets Group Inc.  (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced  Predictive Technology Group, Inc.  (OTCQX: PRED), ...

  • GlobeNewswire

    Predictive Laboratories Team Led by Laboratory Director Kenneth Ward, M.D. Receives 2019 Endometriosis Special Interest Group Prize Paper Award

    SALT LAKE CITY , Oct. 17, 2019 -- Predictive Laboratories, a wholly owned molecular and genetic diagnostics company of Predictive Technology Group (OTC Pink: PRED) focused on.

  • GlobeNewswire

    Predictive Technology Group Engages CLSA Capital Markets Limited, a CITIC Securities Company, to Support Product Launches into China’s Rapidly Growing Women’s Health and Fertility Market

    Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the development of genetic and molecular diagnostics and companion therapeutics, announces that it has engaged CLSA Capital Markets Limited, a CITIC Securities Company, to provide introductions to potential strategic partners and regulatory guidance to support the launch of its proprietary genetic-based products into China’s (PRC) rapidly growing markets for women’s health and fertility.  Terms of the transaction were not disclosed. “Given our genetic library, research and understanding of genetics, endometriosis and other factors that may affect a woman’s fertility, we are excited to bring our noninvasive testing technology to this large, emerging market that already surpasses the U.S. in terms of the number of affected women,” said Bradley Robinson, Chief Executive Officer of Predictive Technology Group.

  • GlobeNewswire

    Predictive Laboratories Launches FertilityDX™

    Predictive Laboratories, a wholly owned molecular and genetic diagnostics company of Predictive Technology Group (OTC Pink: PRED) focused on hard-to-detect diseases, women’s health and infertility, announces the launch of FertilityDX™, a comprehensive genetic testing service that identifies barriers to healthy pregnancy and birth, allowing doctors to tailor fertility treatments. The test launch will be formally announced at the American Society for Reproductive Medicine (ASRM) 2019 Scientific Congress and Expo, Oct. 12-16 in Philadelphia.

  • GlobeNewswire

    Predictive Laboratories Announces Commercialization And Full Market Availability Of ARTguide™ At American Society Of Reproductive Medicine (ASRM) Scientific Congress And Expo

    Predictive Laboratories, a wholly owned molecular and genetic diagnostics company of Predictive Technology Group (OTC Pink: PRED) focused on hard-to-detect diseases, women’s health and infertility, announces the commercialization and full market availability of ARTguide, the first integrated, DNA-based test that evaluates the risk for endometriosis and other genetic causes of infertility in women. After a successful beta launch, Predictive Laboratories completed a laboratory expansion that will allow ARTguide to now be available in fertility clinics across the United States.

  • GlobeNewswire

    Predictive Technology Group Reports Fiscal Year 2019 Financial Results

    SALT LAKE CITY, Sept. 30, 2019 -- Predictive Technology Group, Inc. (OTC PINK: PRED) (the Company), a leader in the use of data analytics for disease identification and.

  • GlobeNewswire

    Predictive Technology Group Names Biologic Industry Leader Jeff Acuff As Chief Commercial Officer Of Predictive Biotech

    Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapies, announces the appointment of Jeff Acuff to the newly created position of Chief Commercial Officer of its wholly owned subsidiary Predictive Biotech. Mr. Acuff will be responsible for the commercial strategy of Predictive Biotech’s existing human cell and tissue product (HCT/P) business, and will implement programs and business development strategies aimed at driving sales and increasing physician awareness of HCT/P treatment options. Additionally, he will oversee the long-term business development strategy for cellular therapies being developed by Predictive Therapeutics.

  • GlobeNewswire

    Predictive Technology Group Accelerates Research Sample Collections to Support Development of Personalized Molecular Diagnostics and Clinical Therapies

    Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapies, announces that its wholly owned subsidiary Predictive Laboratories™ has collected over 2,500 DNA samples along with comprehensive medical records since acquiring its CLIA operations in March 2019. Predictive is broadening its research initiatives by acquiring new sample collections in chronic pain, pregnancy complications, autism, and both female and male infertility. Research is conducted following strict protocols approved by external Institutional Review Boards.  Hundreds of individuals each month have voluntarily consented to share their medical histories and DNA samples for ongoing research.

  • GlobeNewswire

    Predictive Technology Group Announces Launch of PGxPLUS+™ Pharmacogenomic Test and Reaches Clinical Study Enrollment Milestone

    SALT LAKE CITY, Aug. 09, 2019 -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical.

  • GlobeNewswire

    Predictive Technology Group Names Industry Veteran Dr. E. Robert Wassman Co-Laboratory Director of Predictive Laboratories

    SALT LAKE CITY, Aug. 06, 2019 -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical.

  • GlobeNewswire

    Predictive Laboratories to Present New Endometriosis Discoveries in Three Presentations at Leading Scientific Conference Focused on Human Infertility

    Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc. (OTC PINK: PRED), announces the presentation of new genetic findings in endometriosis at the 75th American Society of Reproductive Medicine (ASRM) Scientific Congress & Expo being held October 12-16, 2019 in Philadelphia. The new findings will be presented by Predictive Laboratories’ scientific team.

  • GlobeNewswire

    Predictive Laboratories Announces Research Collaboration with the Preeclampsia Foundation

    Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent precision therapeutic intervention, announces that its wholly owned subsidiary Predictive Laboratories has entered into a research collaboration with the Preeclampsia Foundation to expand the study of genetic factors associated with preeclampsia. The study will advance the Preeclampsia Foundation’s database of collected preeclampsia medical information and will be utilized by Predictive Laboratories to develop a proprietary test for the early detection of women at risk for preeclampsia.

  • GlobeNewswire

    Predictive Technology Group Announces its 11th Consecutive Quarter of Revenue Growth

    Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces the continuation of consecutive quarter revenue growth for the fiscal 2019 fourth quarter ended June 30, 2019.

  • Zacks Small Cap Research

    PRED: Thermo Fisher Deal to Advance Endometriosis Research

    Over the last couple weeks Predictive Technology Group (PRED) has achieved two milestones in its advance towards validating and commercializing its endometriosis diagnostic test. As we discussed in our initiation, the disease impacts an estimated 200 million women worldwide, is frequently misdiagnosed and can be diagnosed early with Predictive’s genetic tests. Thermo Fisher’s collaboration with Predictive Laboratories is focused on studying the genetic factors underlying infertility in women.

  • GlobeNewswire

    Predictive Technology Group Announces the Presentation of New Data Demonstrating the Genetic Basis of Endometriosis at ESHRE

    Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces that data from a study of the genes underlying endometriosis may lead to new pathophysiology insights, improved diagnostics and novel treatment approaches. “Predictive Laboratories is committed to comprehensive disease management and advancing research into the genetic cause of endometriosis to improve the diagnosis and management of patients suffering from the disease,” said Bradley Robinson, CEO of Predictive Technology Group.

  • GlobeNewswire

    Predictive Technology Group Announces the Presentation of New Genetic Findings in Endometriosis at the 35th Annual Meeting of the European Society of Human Reproduction and Embryology

    SALT LAKE CITY, June 20, 2019 -- Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics.

  • PR Newswire

    Thermo Fisher Scientific and Predictive Laboratories Announce Global Infertility Research Collaboration

    Studies aim to elucidate infertility genetics for development of noninvasive test to support decision making and improved outcomes for women pursuing fertility treatment CARLSBAD, Calif. , June 19, 2019 ...

  • Zacks Small Cap Research

    PRED: Fertile Grounds for Genetic Testing

    Predictive Technology Group, Inc. (PRED) is a cellular therapy and genetic diagnostic testing company currently commercializing its portfolio of four placental and Wharton’s Jelly umbilical cord-derived allografts and two gene-based diagnostics. The cellular therapy division provides products derived from amniotic tissue and Wharton’s Jelly that are used by physicians in a variety of healing applications. Genetic diagnostic testing is focused on the women’s health market and is expected to commercialize and seek approval for a test specifically for endometriosis.